🔎 Trials Near Me

Home › Ulcerative Colitis › New York

Ulcerative Colitis clinical trials in New York

31 studies for Ulcerative Colitis are looking for participants at sites in New York.

Cities in New York

A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis

  • Site US-002, Albany
  • Site US-016, Rochester
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 29, 2026 · NCT07845487

Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis

  • New York Gastroenterology Associates - Upper East Side /ID# 281767, New York
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 29, 2026 · NCT07697456

A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis

  • Site 037, New York
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 29, 2026 · NCT07012395

Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis

  • Xencor Investigative Site, Albany
  • Xencor Investigative Site, Rochester
RecruitingPhase 1/2Healthy volunteers welcome
Ages 18 to 75 · All sexes · Updated Sep 29, 2026 · NCT06619990

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

  • Intercity Gastroenterology, Fresh Meadows
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT06979336

A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

  • Westchester Putnam Gastroenterology, Carmel
  • Inflammatory Bowel Disease Center at NYU Langone, New York
  • Icahn School of Medicine at Mount Sinai, New York
  • and 3 more
RecruitingPhase 3
Ages 12 and older · All sexes · Updated Sep 25, 2026 · NCT07196748

A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis

  • Columbia University Medical Center, New York
RecruitingPhase 2/3
Ages 2 to 17 · All sexes · Updated Sep 24, 2026 · NCT05076175

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

  • Icahn School of Medicine at Mount Sinai, New York
  • New York Gastroenterology Associates, New York
  • Care Access - Yonkers, Yonkers
RecruitingPhase 3
Ages 18 to 70 · All sexes · Updated Sep 24, 2026 · NCT06937086

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

  • NYU Langone Hospital - Long Island, Mineola
  • Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
  • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
  • and 1 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT03816345

LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis

  • Stony Brook University, Stony Brook
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Sep 22, 2026 · NCT07415044

LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:

  • Digestive Disease Medicine of Central New York, Utica
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Sep 22, 2026 · NCT07186101

A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

  • Icahn School of Medicine at Mount Sinai, New York
RecruitingPhase 3
Ages 2 to 19 · All sexes · Updated Sep 22, 2026 · NCT04844606

A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)

  • NYU Langone Health, New York
  • Weill Cornell Medical College- New York Presbyterian Hospital, New York
RecruitingPhase 4
Ages 18 to 65 · All sexes · Updated Sep 21, 2026 · NCT06095128

A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

  • MedTraits NY - Site Number: 8400045, Maspeth
  • Weill Cornell Medicine - NewYork-Presbyterian Hospital - Site Number: 8400040, New York
  • New York Gastroenterology Associates - Site Number: 8400009, New York
RecruitingPhase 3
Ages 16 to 80 · All sexes · Updated Sep 15, 2026 · NCT07185009

A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting

  • Westchester Putnam Gastroenterology PC, Carmel
  • Five Towns Gastroenterology, Cedarhurst
  • IMIDeology, Elmhurst
  • and 5 more
RecruitingPhase 4
Ages 18 to 80 · All sexes · Updated Sep 15, 2026 · NCT06581328

Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)

  • New York Gastroenterology Associates ( Site 0253), New York
RecruitingPhase 3
All ages · All sexes · Updated Sep 9, 2026 · NCT06651281

A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis

  • New York Gastroenterology Associates, New York
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT07577856

A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis

  • Fink Children's Ambulatory Care Center, New York
  • Kimmel Pavilion - NYU Langone, New York
  • NYU Grossman School of Medicine, New York
  • and 4 more
RecruitingPhase 2
Ages 2 to 11 · All sexes · Updated Aug 24, 2026 · NCT07470879

A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis

  • Columbia University Medical Center, New York
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Aug 21, 2026 · NCT06636656

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

  • MedTraits NY - Site Number: 8400045, Maspeth
  • Manhattan Clinical Research, LLC - Site Number: 8400069, New York
  • NYU Langone Health - Site Number: 8400091, New York
  • and 4 more
RecruitingPhase 3
Ages 16 to 80 · All sexes · Updated Aug 20, 2026 · NCT07184996

Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission

  • Saratoga Schenectady Gastroenterology Associates, Burnt Hills
  • NYU Langone Health, New York
  • Cornell University, New York
Recruiting
Ages 18 and older · All sexes · Updated Aug 7, 2026 · NCT05230173

BOOM-IBD2 Pivotal Clinical Trial

  • Northwell Health North Shore University Hospital, Manhasset
  • Columbia University Irving Medical Center/New York Presbyterian Hospital, New York
Recruiting
Ages 18 to 85 · All sexes · Updated Aug 6, 2026 · NCT06571669

Zymfentra (Infliximab-dyyb) REal World Cohort STudy

  • New York University, New York
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT07237516

A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

  • Ellipsis Research Group, Brooklyn
  • Smart Medical Research - Jackson Heights, Jackson Heights
  • Pioneer Clinical Research NY, New York
  • and 1 more
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Jul 30, 2026 · NCT06598943

An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis

  • NYU Langone Health, New York
  • Lenox Hill Hospital, Northwell Health, New York
RecruitingObservational study
Ages 18 to 64 · All sexes · Updated Jul 9, 2026 · NCT06398626

A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)

  • New York Presbyterian Hospital, New York
RecruitingPhase 3
Ages 2 to 17 · All sexes · Updated Jun 22, 2026 · NCT06405087

A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis

  • Investigational Site Number: 8400021, New York
  • Investigational Site Number: 8400029, Queens Village
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Apr 23, 2026 · NCT06975722

A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease

  • Mirador Therapeutics Selected Site, New York
  • Mirador Therapeutics Selected Site, Rochester
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Mar 12, 2026 · NCT07113522

Hyperbaric Oxygen Therapy for Ulcerative Colitis (HBOT-UC)

  • State University of New York Upstate Medical University, Syracuse
Recruiting
Ages 18 to 85 · All sexes · Updated Jan 8, 2026 · NCT05987852

Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in Patients With Inflammatory Bowel Disease Using a Novel Remote MONITORing Intervention

  • New York University, New York
RecruitingObservational study
Ages 18 and older · All sexes · Updated May 8, 2025 · NCT06750731

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.